The path forward in prostate cancer therapeutics  

作　　者：Jeanny B Aragon-Ching Ravi A Madan 

机构地区：[1]Department of Genitourinary Medical Oncology,Inova Schar Cancer Institute, Fairfax, VA 22031USA [2]Genitourinary Malignancies Branch,Center for Cancer Research, National CancerInstitute, National Institutes of Health, BethesdaMD. USA

出　　处：《Asian Journal of Andrology》2018年第3期213-214,共2页亚洲男性学杂志（英文版）

摘　　要：The last decade has seen remarkable advances in the treatment of prostatecancer. Until 2010, only docetaxel had demonstrated the ability to improve the survival in metastatic castration-resistant prostate cancer （mCRPC）.The last decade has seen remarkable advances in the treatment of prostatecancer. Until 2010, only docetaxel had demonstrated the ability to improve the survival in metastatic castration-resistant prostate cancer （mCRPC）.

分 类 号：S854.5[农业科学—临床兽医学] Q959.837[农业科学—兽医学]